CN111257565A - 一种衰老细胞的检测试剂盒及其检测方法 - Google Patents
一种衰老细胞的检测试剂盒及其检测方法 Download PDFInfo
- Publication number
- CN111257565A CN111257565A CN201811465286.5A CN201811465286A CN111257565A CN 111257565 A CN111257565 A CN 111257565A CN 201811465286 A CN201811465286 A CN 201811465286A CN 111257565 A CN111257565 A CN 111257565A
- Authority
- CN
- China
- Prior art keywords
- antibody
- kit
- sample
- cells
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 53
- 210000004027 cell Anatomy 0.000 claims abstract description 139
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 53
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims abstract description 46
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims abstract description 46
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 36
- 210000000349 chromosome Anatomy 0.000 claims abstract description 25
- 238000007901 in situ hybridization Methods 0.000 claims abstract description 14
- 238000003125 immunofluorescent labeling Methods 0.000 claims abstract description 9
- 239000000523 sample Substances 0.000 claims description 51
- 238000005406 washing Methods 0.000 claims description 30
- 239000011324 bead Substances 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 238000010186 staining Methods 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 17
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 14
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 14
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 14
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 14
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 14
- 102100035716 Glycophorin-A Human genes 0.000 claims description 12
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 claims description 12
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 12
- 210000000601 blood cell Anatomy 0.000 claims description 12
- 239000002853 nucleic acid probe Substances 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 11
- 238000009396 hybridization Methods 0.000 claims description 11
- 238000011534 incubation Methods 0.000 claims description 11
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 6
- 239000012103 Alexa Fluor 488 Substances 0.000 claims description 5
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 5
- 210000005259 peripheral blood Anatomy 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000012110 Alexa Fluor 594 Substances 0.000 claims description 3
- 239000000834 fixative Substances 0.000 claims description 3
- 108020003215 DNA Probes Proteins 0.000 claims description 2
- 239000003298 DNA probe Substances 0.000 claims description 2
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 2
- 229920002866 paraformaldehyde Polymers 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims description 2
- 238000007447 staining method Methods 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 abstract description 17
- 230000001413 cellular effect Effects 0.000 abstract description 9
- 238000004458 analytical method Methods 0.000 abstract description 6
- 230000000007 visual effect Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 25
- 201000011510 cancer Diseases 0.000 description 21
- 210000001840 diploid cell Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 10
- 238000004140 cleaning Methods 0.000 description 9
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 230000010094 cellular senescence Effects 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 101500016899 Arabidopsis thaliana C-terminally encoded peptide 8 Proteins 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 230000032677 cell aging Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 238000012151 immunohistochemical method Methods 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 101000601048 Homo sapiens Nidogen-2 Proteins 0.000 description 2
- 102100037371 Nidogen-2 Human genes 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 101150035766 CEP8 gene Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102100034533 Histone H2AX Human genes 0.000 description 1
- 101000980932 Homo sapiens Cyclin-dependent kinase inhibitor 2A Proteins 0.000 description 1
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811465286.5A CN111257565A (zh) | 2018-12-03 | 2018-12-03 | 一种衰老细胞的检测试剂盒及其检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811465286.5A CN111257565A (zh) | 2018-12-03 | 2018-12-03 | 一种衰老细胞的检测试剂盒及其检测方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111257565A true CN111257565A (zh) | 2020-06-09 |
Family
ID=70944908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811465286.5A Pending CN111257565A (zh) | 2018-12-03 | 2018-12-03 | 一种衰老细胞的检测试剂盒及其检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111257565A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030152993A1 (en) * | 1998-07-01 | 2003-08-14 | Doeberitz Magnus Von Knebel | Method for the early diagnosis of carcinomas |
US20040023288A1 (en) * | 2002-08-01 | 2004-02-05 | Rudiger Ridder | Method for solution based diagnosis |
CN101583722A (zh) * | 2006-07-14 | 2009-11-18 | 阿维瓦生物科学股份有限公司 | 从生物学样品检测稀有细胞的方法和组合物 |
US20100003189A1 (en) * | 2006-07-14 | 2010-01-07 | The Regents Of The University Of California | Cancer biomarkers and methods of use thereof |
CN104178454A (zh) * | 2013-05-24 | 2014-12-03 | 益善生物技术股份有限公司 | 一种循环肿瘤细胞的富集、分析方法 |
CN106591228A (zh) * | 2016-12-21 | 2017-04-26 | 中国科学院生物物理研究所 | 一种同时抵抗细胞衰老及恶性转化的人多能干细胞的制备方法 |
WO2018164580A1 (en) * | 2017-03-09 | 2018-09-13 | Rijksuniversiteit Groningen | Biomarkers for cellular senescence |
-
2018
- 2018-12-03 CN CN201811465286.5A patent/CN111257565A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030152993A1 (en) * | 1998-07-01 | 2003-08-14 | Doeberitz Magnus Von Knebel | Method for the early diagnosis of carcinomas |
US20040023288A1 (en) * | 2002-08-01 | 2004-02-05 | Rudiger Ridder | Method for solution based diagnosis |
CN101583722A (zh) * | 2006-07-14 | 2009-11-18 | 阿维瓦生物科学股份有限公司 | 从生物学样品检测稀有细胞的方法和组合物 |
US20100003189A1 (en) * | 2006-07-14 | 2010-01-07 | The Regents Of The University Of California | Cancer biomarkers and methods of use thereof |
CN104178454A (zh) * | 2013-05-24 | 2014-12-03 | 益善生物技术股份有限公司 | 一种循环肿瘤细胞的富集、分析方法 |
CN106591228A (zh) * | 2016-12-21 | 2017-04-26 | 中国科学院生物物理研究所 | 一种同时抵抗细胞衰老及恶性转化的人多能干细胞的制备方法 |
WO2018164580A1 (en) * | 2017-03-09 | 2018-09-13 | Rijksuniversiteit Groningen | Biomarkers for cellular senescence |
Non-Patent Citations (2)
Title |
---|
SANTHOSHI BANDLA等: "Comparison of Cancer-Associated Genetic Abnormalities in Columnar-Lined Esophagus tissues with and without Goblet Cells", ANN SURG, vol. 260, no. 1, pages 72 * |
YUJUAN ZHANG等: "Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer", INTERNATIONAL JOURNAL OF CANCER, vol. 136, pages 1228, XP071287954, DOI: 10.1002/ijc.29070 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3490616B1 (en) | Highly-multiplexed fluorescent imaging | |
JP7038062B2 (ja) | 希少細胞を同定する組成物及び方法 | |
CN105954246B (zh) | 一种在人的生物液体样本中检测游离的稀有肿瘤细胞的方法和试剂盒 | |
KR20170094523A (ko) | 생물학적 샘플에서 희귀 사건 분석을 위한 고감도 다중매개변수 방법 | |
CN106970225B (zh) | 一种应用cd45免疫荧光联合cep 8探针鉴定循环肿瘤细胞的试剂盒及其应用 | |
CN106980018B (zh) | 一种应用cd45免疫荧光联合cep17探针鉴定循环肿瘤细胞的试剂盒及其应用 | |
CN106970224B (zh) | 一种应用cd45免疫荧光联合cep探针鉴定循环肿瘤细胞的试剂盒及其应用 | |
US20190078153A1 (en) | Method of analyzing genetically abnormal cells | |
Lei et al. | Combined detection of aneuploid circulating tumor‐derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non‐small‐cell lung cancer | |
CN109439732B (zh) | 一种用于三维无创肿瘤早筛的试剂盒 | |
CN106771185A (zh) | 一种鼻咽癌循环肿瘤细胞检测试剂盒 | |
CN105087775A (zh) | 一种基于稀有细胞检测c-MET/CEP7基因状态的方法及相关试剂盒 | |
CN108866064B (zh) | 一种靶向转移性人乳腺癌细胞的核酸适配体及其应用 | |
CN111351937A (zh) | 一种mmr蛋白表达缺失检测试剂盒及其检测方法 | |
CN111257565A (zh) | 一种衰老细胞的检测试剂盒及其检测方法 | |
WO2021010369A1 (ja) | ウイルスを用いた循環腫瘍細胞の検出方法 | |
RU2554746C1 (ru) | Способ получения суммарной фракции внеклеточных нуклеиновых кислот из крови | |
Pan et al. | Flow cytometric characterization of acute leukemia reveals a distinctive “blast gate” of murine T-lymphoblastic leukemia/lymphoma | |
CN102174465A (zh) | 一种从组织中分离富集靶细胞的方法 | |
JP7289460B2 (ja) | 分析および診断目的のために生体試料を固定化する方法 | |
US10139398B2 (en) | Methods and combinations of signaling markers for assessment of disease states | |
EA201800291A1 (ru) | Биочип для мультиплексного анализа и способ исследования клеток при диагностике онкологических заболеваний | |
US20240011989A1 (en) | Method for identification of viruses and diagnostic kit using the same | |
CN111826445B (zh) | miR-1468-5p在评估宫颈癌患者PD-L1表达中应用 | |
Keagle et al. | Basic cytogenetics laboratory procedures |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 201800 building 6, No. 1585, Yuanguo Road, Anting Town, Jiading District, Shanghai Applicant after: Shanghai Cell Therapy Group Co.,Ltd. Applicant after: SHANGHAI CELL THERAPY Research Institute Address before: 201800 building 6, No. 1585, Yuanguo Road, Anting Town, Jiading District, Shanghai Applicant before: SHANGHAI CELL THERAPY GROUP Co.,Ltd. Country or region before: China Applicant before: SHANGHAI CELL THERAPY Research Institute |
|
CB02 | Change of applicant information |